Navigating Chronic Pain in Patients with Cirrhosis: Unique Analgesic Considerations and Non-Pharmacologic Options
Curr Hepatol Rep. 2026;25(1):15. doi: 10.1007/s11901-026-00735-9. Epub 2026 May 2.
ABSTRACT
PURPOSE OF REVIEW: Chronic pain affects 40-80% of patients with chronic liver disease, yet management remains challenging due to impaired drug metabolism, limited evidence, and the absence of disease-specific guidelines. This review summarizes the evidence for pharmacologic and non-pharmacologic pain management strategies in patients with cirrhosis.
RECENT FINDINGS: Nearly every analgesic class carries risk in patients with cirrhosis, and most prescribing recommendations are based on pharmacokinetic data and expert opinion rather than clinical trials. Opioid prescribing has declined in recent years, but nonopioid alternatives have not increased proportionally. Non-pharmacologic modalities have been scarcely studied in this population. Shared comorbidities and risk factors, including alcohol use, metabolic disease, sleep disturbances, and psychiatric conditions, represent modifiable therapeutic targets that may improve pain while altering liver disease trajectory.
SUMMARY: Pain management in patients with cirrhosis requires an individualized, multimodal approach integrating pharmacologic therapy, non-pharmacologic interventions, and comorbidity management. Further research, including both well-designed observational studies and prospective trials, is needed to generate evidence-based guidance for this underserved population.
PMID:42083575 | PMC:PMC13135597 | DOI:10.1007/s11901-026-00735-9